ANI Pharmaceuticals Stock Surges 53% YTD: Time to Buy or Sell?
ANIP's 53% YTD surge fuels strong 2025 financial performance, a raised outlook and powerful momentum in its rare disease portfolio.
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields - Metsera ( NASDAQ:MTSR ) , Pfizer ( NYSE:PFE )
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Here's Why Shares in Theravance Biopharma Exploded Today
The company is making excellent progress on all its strategic goals.
Theravance's Q3 Earnings Surpass Estimates, Revenues Match
TBPH delivers a third-quarter profit, beating estimates, and 19% revenue growth, fueled by rising collaboration income from Viatris related to Yupelri sales.
Viatris ( VTRS ) Q3 2025 Earnings Call Transcript
Image source: The Motley Fool.Thursday, Nov. 6, 2025, at 8:30 a.m. ETNeed a quote from a Motley Fool analyst? Email [email protected] reading ...
Viatris Tops Q3 Earnings & Revenue Estimates, Ups '25 Guidance
Viatris tops Q3 earnings and revenue estimates, lifts 2025 outlook, and expands its Japan presence with Aculys Pharma deal.
Viatris ( VTRS ) Beats Q3 Earnings and Revenue Estimates
Viatris (VTRS) delivered earnings and revenue surprises of +6.35% and +3.09%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates
Lexicon Pharmaceuticals reported third quarter 2025 financial results and provided an update on key corporate milestones and accomplishments.
Countdown to Viatris ( VTRS ) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
Evaluate the expected performance of Viatris (VTRS) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Charles River Laboratories ( CRL ) Q3 Earnings and Revenues Surpass Estimates
Charles River (CRL) delivered earnings and revenue surprises of +4.74% and +2.06%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Buy?
CorMedix and Theravance take sharply different routes to small-cap biotech growth - one fueled by sales traction, the other by pipeline promise.
Viatris ( VTRS ) Expected to Beat Earnings Estimates: Should You Buy?
Viatris (VTRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields - Merck & Co ( NYSE:MRK ) , Viatris ( NASDAQ:VTRS )
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
QUVIVIQ sales up >130% driving Idorsia toward profitability - 9M 2025 results
Ad hoc announcement pursuant to Art. 53 LR ...
Is Viatris ( VTRS ) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Will Viatris ( VTRS ) Beat Estimates Again in Its Next Earnings Report?
Viatris (VTRS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Plus Therapeutics Updates on CNSide® Diagnostic Platform Launch - Plus Therapeutics ( NASDAQ:PSTV )
Expands commercial readiness and diagnostic, manufacturing footprint Appoints new leadership in commercial strategy and technical operations
Plus Therapeutics Updates on CNSide® Diagnostic Platform Launch
Expands commercial readiness and diagnostic, manufacturing footprint ...
Viatris Acquires Aculys Pharma to Expand Neurology Portfolio in Japan
VTRS acquires Aculys Pharma to boost its CNS portfolio in Japan, gaining rights to pitolisant and Spydia for narcolepsy and seizure management, respectively.
Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs - Amphastar Pharma ( NASDAQ:AMPH ) , Amneal Pharmaceuticals ( NASDAQ:AMRX )
The Trump administration is reportedly planning to exclude imported generic drugs from tariffs.
Is Pacer US Small Cap Cash Cows ETF ( CALF ) a Strong ETF Right Now?
Smart Beta ETF report for CALF ...
Theravance Bio ( TBPH ) Up 9.8% Since Last Earnings Report: Can It Continue?
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should Pacer US Small Cap Cash Cows ETF ( CALF ) Be on Your Investing Radar?
Style Box ETF report for CALF ...
Zacks Investment Ideas feature highlights: Church & Dwight, Eli Lilly and Viatris
CEOs at Church & Dwight, Eli Lilly, and Viatris are buying shares after stock pullbacks, signaling insider confidence.
Insider Watch: 3 CEOs Buying the Dip
Large-cap stocks CHD, LLY, and VTRS have seen their respective CEOs make purchases over the last month. What do they see?
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
Are the Dow's biggest yields a bargain or a warning sign? Here's how the top payouts stack up, and what that could mean for income investors.
Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update
- Positive 12-month Phase 1/2 clinical data in adult cohort and early pediatric clinical data support potential for meaningful vision restoration with OPGx-LCA5 - - FDA grants Regenerative Medicine Advanced Therapy ( RMAT ) designation for OPGx-LCA5 -
Missed Opt-Out Deadline Could Cost Investors Millions In Perrigo Fraud Suit - Perrigo ( NYSE:PRGO )
Perrigo restated over $1 billion in financial misstatements from 2015-2017. Shares plunged more than 62% after accounting and earnings disclosures. The next 100%+ earnings move could hit this month. See how to find it live on Wednesday →
Theravance's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y
TBPH posts better-than-expected second-quarter 2025 results, boosted by Yupelri sales and licensing gains.
Theravance Sales Jump 83 Percent
Theravance Biopharma ( NASDAQ:TBPH ) , a biopharmaceutical company focused on respiratory medicines and rare disease therapeutics, reported its Q2 2025 results on August 12, 2025. The company's revenue ( GAAP ) grew to $26.2 million, slightly ahead of analyst estimates at $25.93 million.
Why Is Amphastar Pharma Stock Soaring Tuesday? - Amphastar Pharma ( NASDAQ:AMPH ) , Fresenius Medical Care ( NYSE:FMS )
FDA approves Amphastar's generic Venofer, eyeing $80 million-$100 million in sales. Amphastar shares were boosted by an analyst upgrade to buy with a $36 target. This simple system has nailed 1,000+ post-earnings winners. Get in before Q3 trades take off → On Monday, the U.S.
Viatris Stock Rises as Q2 Earnings & Revenues Beat Estimates
VTRS beats on Q2 estimates with strength in branded drugs and growth in Greater China, lifting shares.
Viatris ( VTRS ) Tops Q2 Earnings and Revenue Estimates
Viatris (VTRS) delivered earnings and revenue surprises of +10.71% and +2.40%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Lexicon ( LXRX ) Q2 Revenue Soars 1,706%
Lexicon Pharmaceuticals ( NASDAQ:LXRX ) , a biopharma company focused on developing treatments for diabetes, cardiovascular, and neurological diseases, released its second quarter 2025 financial results on August 6, 2025. The most important news: revenue ( GAAP ) reached $28.9 million in the ...
Viatris ( VTRS ) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Get a deeper insight into the potential performance of Viatris (VTRS) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Viatris Poised to Report Q2 Earnings: What's in Store for the Stock?
VTRS braces for Q2 results as branded drug growth in Europe and China offsets generic headwinds in North America.
Strong sales acceleration of QUVIVIQ drives Idorsia toward profitability - H1 2025 results
Ad hoc announcement pursuant to Art. 53 LR ...
Judge Rules Mylan Did Not Infringe Novo Nordisk Patent In Wegovy Generic Case - Novo Nordisk ( NYSE:NVO )
Court grants Mylan judgment of no direct, contributory or induced infringement on U.S. Patent. Mylan's proposed drug label did not instruct use without other therapeutic agents, undermining Novo's case. Up Next: Get 5 Dark Horse Stocks Wall Street Is Quietly Loading Up On
Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer
WARREN, N.J., July 22, 2025 ( GLOBE NEWSWIRE ) -- Aquestive Therapeutics, Inc. ( NASDAQ: AQST ) ( "Aquestive" or the "Company" ) , a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced ...
Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer - Aquestive Therapeutics ( NASDAQ:AQST )
WARREN, N.J., July 22, 2025 ( GLOBE NEWSWIRE ) -- Aquestive Therapeutics, Inc.
VTRS Down on Late-Stage Study Failure of Eye Disease Drug
VTRS slides after phase III trial failure for blepharitis drug MR-139, adding pressure to an already struggling stock.
Viatris Hits Snag In Eye Drug Study-Phase 3 Plans Under Review - Viatris ( NASDAQ:VTRS )
Viatris' pimecrolimus ophthalmic ointment failed to meet the primary endpoint in a Phase 3 blepharitis study. The company may revise its Phase 3 plans after the trial showed no full resolution of eyelid debris after six weeks.
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Geron Corporation, Viatris, Everus Construction, and SoundHound - Everus Construction Group ( NYSE:ECG ) , Geron ( NASDAQ:GERN )
SAN DIEGO, July 18, 2025 ( GLOBE NEWSWIRE ) -- Johnson Fistel, PLLP, is investigating potential violations of federal and state securities laws by certain officers and directors of Geron Corporation GERN, Viatris Inc. VTRS, Everus Construction Group, Inc. ECG, and SoundHound AI, Inc.
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics
CPRX, ZVRA, TBPH, ALDX, and LRMR shine amid tariff threats, thanks to strong pipelines, demand, and rising earnings estimates.
5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats
Innovation is at its peak in the Zacks Medical-Drugs industry. CPRX, ZVRA, TBPH, ALDX and LRMR may prove to be good additions to one's portfolio.
Viatris Eye Drops Data Shows Promise For Blurred Near Vision - Viatris ( NASDAQ:VTRS ) , Opus Genetics ( NASDAQ:IRD )
MR-141 met primary endpoint with ≥3-line near vision gain at 12 hours post-dose on Day 8 vs. placebo ( p<0.0001 ) . No serious adverse events; most common side effects were mild, including eye redness and site irritation. Market-moving news hits Benzinga Pro first-get a 30-minute edge and ...
Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
• Study met its primary and key secondary endpoints, demonstrating rapid and sustained improvement in near visual acuity • Safety profile consistent with previous clinical trials and no treatment-related serious adverse events reported in the study • No evidence of tachyphylaxis was observed in ...
Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia - Opus Genetics ( NASDAQ:IRD )
Study met its primary and key secondary endpoints, demonstrating rapid and sustained improvement in near visual acuity Safety profile consistent with previous clinical trials and no treatment-related serious adverse events reported in the study
Kuehn Law Encourages Investors of Viatris Inc. to Contact Law Firm - Viatris ( NASDAQ:VTRS )
NEW YORK, June 10, 2025 ( GLOBE NEWSWIRE ) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Viatris Inc. VTRS breached their fiduciary duties to shareholders.
Zacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals and Viatris
SDZNY, TEVA, and VTRS show resilience with strong biosimilar pipelines and margin strategies amid industry headwinds.
